Quick-Med Technologies, a life sciences company developing technologies for the healthcare and consumer markets, has gained approval to manufacture, market and sell its Nimbus antimicrobial technology in India.

Quick-Med’s patented technology, Nimbus, is a antimicrobial technology designed for wound care and other medical applications.

Viridis BioPharma, an India-based manufacturer and marketer of medical devices, received approval by the Food and Drug Administration (FDA) of India to manufacture and market gauze wound dressings that incorporate Nimbus antimicrobial technology.

Quick-Med CEO Ladd Greeno said that the approval of their proprietary Nimbus antimicrobial wound care technology by the India FDA marks an important milestone for both Quick-Med and Viridis.

Viridis BioPharma CEO Dilip Mehta said that they see this approval to manufacture and market Nimbus technology based antimicrobial gauze dressings as a paradigm shift in the burn and wound care management. There will be a protection afforded against infections to a major percentage of the affected population.